Santen Pharmaceutical Co., Ltd. (TYO: 4536)
Japan
· Delayed Price · Currency is JPY | Market Cap | 635.32B |
| Revenue (ttm) | 304.35B |
| Net Income (ttm) | 26.85B |
| Shares Out | 349.94M |
| EPS (ttm) | 73.64 |
| PE Ratio | 24.65 |
| Forward PE | 19.99 |
| Dividend | 34.00 (1.86%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 1,155,300 |
| Open | 1,790.00 |
| Previous Close | 1,827.50 |
| Day's Range | 1,780.50 - 1,822.00 |
| 52-Week Range | 1,255.00 - 1,878.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha... [Read more]
Financial Performance
Financial StatementsNews
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...